[
  {
    "question": {
      "question_id": "cs03_q09_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 5,
      "question_type": "longitudinal",
      "prompt": "Based on the first five weeks of trial data, are there any safety signals in the lab panels?",
      "ground_truth": {
        "canonical_answer": "No. All lab panels are within normal limits across all sites. Hepatic, renal, and hematology markers show no adverse trends. The trial is in the enrollment ramp-up phase.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_003",
          "clinical_signal_03_ep_005"
        ],
        "key_facts": []
      }
    },
    "answer": {
      "question_id": "cs03_q09_longitudinal",
      "answer_text": "Based on the available information from the first five weeks of trial data, there are no reported safety signals in the lab panels. The daily operations summaries from 2024-03-04 to 2024-04-01 (covering the first five weeks) document enrollment numbers, site-level participation, and concomitant medication use (e.g., statins), but do not mention any abnormalities or safety concerns in laboratory results [clinical_signal_03_ep_001][clinical_signal_03_ep_002][clinical_signal_03_ep_003][clinical_signal_03_ep_004][clinical_signal_03_ep_005]. Additionally, metadata for these episodes consistently indicate \"signal_density: none,\" suggesting no safety signals were detected during this period [clinical_signal_03_ep_001].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_987ef34d769f43828678a005",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 753
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_987ef34d769f43828678a005",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_3ce478d797a44bb6a883ee0d",
              "name": "memory_search",
              "arguments": {
                "query": "safety signals lab panels first five weeks trial",
                "limit": 5
              }
            }
          ],
          "tokens_used": 1055
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_3ce478d797a44bb6a883ee0d",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.03252247488101534, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 80\\n- Active: 80\\n- Screen Failures Cumulative: 5\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 8\\n- Site 01 Active: 8\\n- Site 01 Statin Concomitant: 2\\n- Site 02 Enrolled: 6\\n- Site 02 Active: 6\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 7\\n- Site 03 Active: 7\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 5\\n- Site 04 Active: 5\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 6\\n- Site 05 Active: 6\", \"score\": 0.031754032258064516, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.031746031746031744, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.03076923076923077, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_be64487ada894377aa31d91a",
              "name": "memory_search",
              "arguments": {
                "query": "lab panels safety signals first five weeks",
                "filters": {
                  "start_date": "2024-03-04",
                  "end_date": "2024-04-08"
                },
                "limit": 5
              }
            }
          ],
          "tokens_used": 2595
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_be64487ada894377aa31d91a",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.03252247488101534, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 80\\n- Active: 80\\n- Screen Failures Cumulative: 5\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 8\\n- Site 01 Active: 8\\n- Site 01 Statin Concomitant: 2\\n- Site 02 Enrolled: 6\\n- Site 02 Active: 6\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 7\\n- Site 03 Active: 7\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 5\\n- Site 04 Active: 5\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 6\\n- Site 05 Active: 6\", \"score\": 0.031754032258064516, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.031746031746031744, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.03076923076923077, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_7f8ccae83d39467f83ccce2b",
              "name": "memory_search",
              "arguments": {
                "query": "safety signals lab results first five weeks",
                "filters": {
                  "start_date": "2024-03-04",
                  "end_date": "2024-04-08"
                },
                "limit": 5
              }
            }
          ],
          "tokens_used": 4136
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_7f8ccae83d39467f83ccce2b",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Based on the available information from the first five weeks of trial data, there are no reported safety signals in the lab panels. The daily operations summaries from 2024-03-04 to 2024-04-01 (covering the first five weeks) document enrollment numbers, site-level participation, and concomitant medication use (e.g., statins), but do not mention any abnormalities or safety concerns in laboratory results [clinical_signal_03_ep_001][clinical_signal_03_ep_002][clinical_signal_03_ep_003][clinical_signal_03_ep_004][clinical_signal_03_ep_005]. Additionally, metadata for these episodes consistently indicate \"signal_density: none,\" suggesting no safety signals were detected during this period [clinical_signal_03_ep_001].",
          "tokens_used": 4346
        }
      ],
      "tool_calls_made": 4,
      "total_tokens": 12885,
      "wall_time_ms": 12167.396177072078,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2863 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_001",
        "clinical_signal_03_ep_002",
        "clinical_signal_03_ep_003",
        "clinical_signal_03_ep_004",
        "clinical_signal_03_ep_005"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_001",
      "clinical_signal_03_ep_002",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_005"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_001",
      "clinical_signal_03_ep_002",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_004",
      "clinical_signal_03_ep_005"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q10_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 5,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient data at this point to evaluate the safety profile of LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Only 5 weeks of data from the enrollment ramp phase are available. The subject population is too small and exposure duration too short to draw conclusions about the drug's safety profile.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_003"
        ],
        "key_facts": []
      }
    },
    "answer": {
      "question_id": "cs03_q10_evidence",
      "answer_text": "The available data includes multiple daily operations summaries from March to April 2024, reporting enrollment numbers and adverse events (AEs) for LNS-4821. Adverse events such as fatigue, headache, dizziness, diarrhea, arthralgia, and upper respiratory infection have been recorded, mostly graded as mild (Grade 1), with relatedness assessments ranging from \"possibly related\" to \"unlikely related\" [clinical_signal_03_ep_003, clinical_signal_03_ep_005]. All reported AEs have resolved [clinical_signal_03_ep_003, clinical_signal_03_ep_005]. Enrollment has progressed to 100 randomized subjects across five sites as of March 25, 2024 [clinical_signal_03_ep_004].\n\nHowever, the data appears limited to baseline and early treatment phases, with no serious adverse events (SAEs) reported so far. The sample size and observation period may not yet be sufficient to fully evaluate the long-term or rare safety risks of LNS-4821. Therefore, while preliminary safety data is being collected and monitored, the current information is insufficient for a comprehensive safety profile assessment [clinical_signal_03_ep_003, clinical_signal_03_ep_005].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_c255197d04dd4c4092add634",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 754
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_c255197d04dd4c4092add634",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_3b57ca88eec04af4b1215f37",
              "name": "memory_search",
              "arguments": {
                "query": "safety profile of LNS-4821",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1058
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_3b57ca88eec04af4b1215f37",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.03252247488101534, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Adverse Events\\n- AE ID: AE-0008, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0009, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0010, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.0315136476426799, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 60\\n- Active: 60\\n- Screen Failures Cumulative: 4\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01 Enrolled: 6\\n- Site 01 Active: 6\\n- Site 01 Statin Concomitant: 1\\n- Site 02 Enrolled: 4\\n- Site 02 Active: 4\\n- Site 02 Statin Concomitant: 1\\n- Site 03 Enrolled: 5\\n- Site 03 Active: 5\\n- Site 03 Statin Concomitant: 1\\n- Site 04 Enrolled: 4\\n- Site 04 Active: 4\\n- Site 04 Statin Concomitant: 1\\n- Site 05 Enrolled: 5\\n- Site 05 Active: 5\", \"score\": 0.03149801587301587, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n### Adverse Events\\n- AE ID: AE-0013, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\\n- AE ID: AE-0014, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\\n- AE ID: AE-0015, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0016, Description: upper respiratory infection, Grade: 1, Relat\", \"score\": 0.03149801587301587, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_68aaca3146f54fb2a418768b",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_004",
                  "clinical_signal_03_ep_003",
                  "clinical_signal_03_ep_001",
                  "clinical_signal_03_ep_002",
                  "clinical_signal_03_ep_005"
                ]
              }
            }
          ],
          "tokens_used": 2459
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_68aaca3146f54fb2a418768b",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The available data includes multiple daily operations summaries from March to April 2024, reporting enrollment numbers and adverse events (AEs) for LNS-4821. Adverse events such as fatigue, headache, dizziness, diarrhea, arthralgia, and upper respiratory infection have been recorded, mostly graded as mild (Grade 1), with relatedness assessments ranging from \"possibly related\" to \"unlikely related\" [clinical_signal_03_ep_003, clinical_signal_03_ep_005]. All reported AEs have resolved [clinical_signal_03_ep_003, clinical_signal_03_ep_005]. Enrollment has progressed to 100 randomized subjects across five sites as of March 25, 2024 [clinical_signal_03_ep_004].\n\nHowever, the data appears limited to baseline and early treatment phases, with no serious adverse events (SAEs) reported so far. The sample size and observation period may not yet be sufficient to fully evaluate the long-term or rare safety risks of LNS-4821. Therefore, while preliminary safety data is being collected and monitored, the current information is insufficient for a comprehensive safety profile assessment [clinical_signal_03_ep_003, clinical_signal_03_ep_005].",
          "tokens_used": 2764
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 7035,
      "wall_time_ms": 9803.94349200651,
      "budget_violations": [
        "Cumulative result token limit exceeded: 5747 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_004"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_004"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_004"
    ]
  }
]